嗜麦芽窄食单胞菌
抗菌剂
抗生素
头孢菌素
抗生素耐药性
微生物学
医学
抗药性
重症监护医学
左氧氟沙星
肺炎
生物
抗感染药
铜绿假单胞菌
多重耐药
多粘菌素
后天抵抗
药物治疗
细菌
作者
Paiboon Vattanaviboon,Skorn Mongkolsuk,Nisanart Charoenlap
出处
期刊:Acta microbiologica et immunologica Hungarica (Print)
[Akadémiai Kiadó]
日期:2025-09-16
卷期号:72 (3): 171-179
被引量:3
标识
DOI:10.1556/030.2025.02676
摘要
Stenotrophomonas maltophilia has emerged as an opportunistic pathogen that causes life-threatening hospital-acquired infections. This microorganism possesses a diverse array of chromosome-encoded antimicrobial resistance genes, which render it inherently multidrug-resistant (MDR). Its ability to acquire additional antimicrobial resistance via mutations and the horizontal transfer of resistome elements from neighboring microbial communities has further contributed to the development of extensively drug-resistant (XDR) and even pandrug-resistant (PDR) strains. These strains are resistant to routinely used antibiotics, including the first-line drug trimethoprim/sulfamethoxazole as well as levofloxacin and minocycline. Recently, cefiderocol - a siderophore-conjugated cephalosporin - was developed for clinical use. This antibiotic has shown high in vitro efficacy against clinically relevant MDR gram-negative pathogens. Cefiderocol efficiently transverses the outer membrane of bacteria via iron transport systems and exhibits high stability against β-lactamases. An injectable form of cefiderocol has received Food and Drug Administration approval for the treatment of complicated urinary tract infections, hospital-acquired bacterial pneumonia, and ventilator-associated bacterial pneumonia caused by drug-resistant gram-negative bacteria. Clinical data on the use of cefiderocol for S. maltophilia infections remain limited, however, some in vitro, in vivo, and case studies have demonstrated its efficacy and successful treatment of MDR S. maltophilia infections. Given the narrow range of therapeutic options currently available, cefiderocol presents a promising alternative for the effective management of severe S. maltophilia infections. Nevertheless, the potential for the emergence of resistance remains a significant concern, as emerging evidence suggests that S. maltophilia may acquire resistance following exposure to this antibiotic.
科研通智能强力驱动
Strongly Powered by AbleSci AI